Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer

Shinkichi Takamori, Kazuki Takada, Koichi Azuma, Yumiko Jogo, Fumihiko Kinoshita, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Gouji Toyokawa, Fumihiko Hirai, Tetsuzo Tagawa, Isamu Okamoto, Yoichi Nakanishi, Akihiko Kawahara, Jun Akiba, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Background/Aim: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with smallcell lung cancer (SCLC), the prognostic significance of PDL2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PDL2 expression in patients with SCLC. Patients and Methods: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-human PD-L1 antibody (clone SP142) and a monoclonal anti-human PDL2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1%. Results: Among 38 patients, 15 (39.5%) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). Conclusion: PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations.

元の言語英語
ページ(範囲)5903-5907
ページ数5
ジャーナルAnticancer research
38
発行部数10
DOI
出版物ステータス出版済み - 10 1 2018

Fingerprint

Small Cell Lung Carcinoma
Cell Death
Ligands
Lung Neoplasms
Programmed Cell Death 1 Ligand 2 Protein
Antibodies
Clone Cells
Disease-Free Survival
Survival
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Takamori, S., Takada, K., Azuma, K., Jogo, Y., Kinoshita, F., Kozuma, Y., ... Maehara, Y. (2018). Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer. Anticancer research, 38(10), 5903-5907. https://doi.org/10.21873/anticanres.12934

Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer. / Takamori, Shinkichi; Takada, Kazuki; Azuma, Koichi; Jogo, Yumiko; Kinoshita, Fumihiko; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Akamine, Takaki; Toyokawa, Gouji; Hirai, Fumihiko; Tagawa, Tetsuzo; Okamoto, Isamu; Nakanishi, Yoichi; Kawahara, Akihiko; Akiba, Jun; Oda, Yoshinao; Maehara, Yoshihiko.

:: Anticancer research, 巻 38, 番号 10, 01.10.2018, p. 5903-5907.

研究成果: ジャーナルへの寄稿記事

Takamori, S, Takada, K, Azuma, K, Jogo, Y, Kinoshita, F, Kozuma, Y, Matsubara, T, Haratake, N, Akamine, T, Toyokawa, G, Hirai, F, Tagawa, T, Okamoto, I, Nakanishi, Y, Kawahara, A, Akiba, J, Oda, Y & Maehara, Y 2018, 'Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer', Anticancer research, 巻. 38, 番号 10, pp. 5903-5907. https://doi.org/10.21873/anticanres.12934
Takamori, Shinkichi ; Takada, Kazuki ; Azuma, Koichi ; Jogo, Yumiko ; Kinoshita, Fumihiko ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Akamine, Takaki ; Toyokawa, Gouji ; Hirai, Fumihiko ; Tagawa, Tetsuzo ; Okamoto, Isamu ; Nakanishi, Yoichi ; Kawahara, Akihiko ; Akiba, Jun ; Oda, Yoshinao ; Maehara, Yoshihiko. / Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer. :: Anticancer research. 2018 ; 巻 38, 番号 10. pp. 5903-5907.
@article{04f43939226d48b88722d9ed1538a1ca,
title = "Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer",
abstract = "Background/Aim: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with smallcell lung cancer (SCLC), the prognostic significance of PDL2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PDL2 expression in patients with SCLC. Patients and Methods: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-human PD-L1 antibody (clone SP142) and a monoclonal anti-human PDL2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1{\%}. Results: Among 38 patients, 15 (39.5{\%}) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). Conclusion: PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations.",
author = "Shinkichi Takamori and Kazuki Takada and Koichi Azuma and Yumiko Jogo and Fumihiko Kinoshita and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Takaki Akamine and Gouji Toyokawa and Fumihiko Hirai and Tetsuzo Tagawa and Isamu Okamoto and Yoichi Nakanishi and Akihiko Kawahara and Jun Akiba and Yoshinao Oda and Yoshihiko Maehara",
year = "2018",
month = "10",
day = "1",
doi = "10.21873/anticanres.12934",
language = "English",
volume = "38",
pages = "5903--5907",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Prognostic impact of PD-L2 expression and association with PD-L1 in patients with small-cell lung cancer

AU - Takamori, Shinkichi

AU - Takada, Kazuki

AU - Azuma, Koichi

AU - Jogo, Yumiko

AU - Kinoshita, Fumihiko

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Akamine, Takaki

AU - Toyokawa, Gouji

AU - Hirai, Fumihiko

AU - Tagawa, Tetsuzo

AU - Okamoto, Isamu

AU - Nakanishi, Yoichi

AU - Kawahara, Akihiko

AU - Akiba, Jun

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background/Aim: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with smallcell lung cancer (SCLC), the prognostic significance of PDL2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PDL2 expression in patients with SCLC. Patients and Methods: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-human PD-L1 antibody (clone SP142) and a monoclonal anti-human PDL2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1%. Results: Among 38 patients, 15 (39.5%) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). Conclusion: PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations.

AB - Background/Aim: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with smallcell lung cancer (SCLC), the prognostic significance of PDL2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PDL2 expression in patients with SCLC. Patients and Methods: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-human PD-L1 antibody (clone SP142) and a monoclonal anti-human PDL2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1%. Results: Among 38 patients, 15 (39.5%) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). Conclusion: PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations.

UR - http://www.scopus.com/inward/record.url?scp=85054071479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054071479&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12934

DO - 10.21873/anticanres.12934

M3 - Article

VL - 38

SP - 5903

EP - 5907

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -